% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Benzel:141151,
author = {J. Benzel$^*$ and V. Fendrich},
title = {{F}amilial {P}ancreatic {C}ancer.},
journal = {Oncology research and treatment},
volume = {41},
number = {10},
issn = {2296-5262},
address = {Basel},
publisher = {Karger},
reportid = {DKFZ-2018-01682},
pages = {611 - 618},
year = {2018},
abstract = {Familial pancreatic cancer accounts for $10\%$ of all
patients with pancreatic cancer. Because the 5-year survival
rate of pancreatic cancer is only $7\%,$ screening programs
for high-risk individuals are essential and might be
advantageous. Pancreatic ductal adenocarcinoma mostly shows
symptoms at an advanced state and treatment is not efficient
enough to cure most patients. People with hereditary tumor
syndromes or their affected relatives can also be included
in such screening programs. Besides the collection of data
to investigate the background of the disease, these
screening programs aim to diagnose and treat precursor
lesions so that more dangerous, invasive lesions are
prevented. These precursor lesions can be pancreatic
intraepithelial neoplasia, intraductal papillary mucinous
neoplasm, and mucinous cystic neoplasm. This review
summarizes the latest knowledge of pancreatic screening
programs, shows the procedure of pancreatic cancer
screening, and gives an overview of current guidelines.},
subtyp = {Review Article},
cin = {B062},
ddc = {350},
cid = {I:(DE-He78)B062-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30269130},
doi = {10.1159/000493473},
url = {https://inrepo02.dkfz.de/record/141151},
}